Paediatric Chemotherapy Regimens

Paediatric Chemotherapy regimens

The information contained in these regimens is a statement of consensus of NCCP and Consultant Paediatric Medical Oncologists and Paediatric Haematologist professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. The treatment regimen to be used should take into account factors such as histology, molecular pathology, age, performance status, co-morbidities and the patient’s preference. Each treatment regimen has advantages and disadvantages, and there may be more than one good option.  In addition, treatment choices can change over time as more evidence becomes available. Use of these documents is the responsibility of the prescribing clinician and is subject to the HSE.ie terms of use.

Please email any comments or feedback on these regimens to oncologydrugs@cancercontrol.ie.

Paediatric Chemotherapy regimens

Regimen Indication

Blinatumomab Paediatric Therapy

Regimen

P0567a

As monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogenic hematopoietic stem cell transplantation

Dinutuximab beta and Isotretinoin Therapy

Regimen

P0548a

For the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. Prior to the treatment of relapsed neurobasltoma, any actively progressing disease should be stabilised by other suitable measures.